March 13, 2026 USA
Pharma Industry:The New Rules of Global Partnering
In her column, Helena Strigård highlights Diamyd Medical as an example of a company preparing for global partnering. CEO Ulf Hannelius, CFO Niklas Axelsson and board member Dr. Karin Rosén discussed the company’s development of a disease-modifying treatment for type 1 diabetes based on antigen-specific immunotherapy and the importance of understanding the U.S. diabetes care ecosystem as the company approaches a pre-readout of its Phase 3 study.
Read the article here
Information presented here are not press releases and may include excerpts from and links to externally published content. Diamyd Medical is not responsible for externally published content.